Clinical trial
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
NCT00346684 · University of Cologne, Other · Completed
Key facts
| NCT number | NCT00346684 |
|---|---|
| Title | Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL) |
| Official title | Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab. |
| Lead sponsor | University of Cologne, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) |
| Intervention type | Drug |
| Interventions | Rituximab |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2007 |
| First posted | Jun 30, 2006 |
| Last update posted | Aug 12, 2008 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: